Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan
TOKYO, Mar 23, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor diอ่านต่อไป